The wait list is only one aspect of the business where orders may come from.
What is not included in the wait list and is the unknown is how many pulse devices will go to the following as per the annual report-
"partnership with Heartbeat Health in the U.S., a network of cardiologists that will enable the prescription of the Pulse to consumers through both clinical and our e-Commerce channels"
Also there is a current pipeline of 5 million for clinical trials for the Atcor business. How much this could expand when pulse is ready is unknown but could be quite substantial especially with a previous post about Fda wanting more remote tech driven trials.
Cardiex have big pharma PARTNERS who have 500k plus patients in there clinical trial pool.
Saying all this i tend to agree with some previous posts that the time for talking is past and the time for executing is NOW.
Add to My Watchlist
What is My Watchlist?
